D2C7 for Adult Patients With Recurrent Malignant Glioma

Inclusion Criteria: * Patients must have a recurrent supratentorial WHO grade III or IV malignant glioma based on imaging studies; * Prior histopathology consistent with a supratentorial WHO grade III or IV malignant glioma; * Following biopsy, prior to administration of D2C7-IT, the presence of recurrent tumor must be confirmed by histopathological analysis; * Age ≥ 18 years of age; * Karnofsky Performance Status (KPS) ≥ 70%; * Laboratory Values: * Platelet count ≥ 100,000/µl unsupported is necessary for eligibility on the study; however, because of risks of intracranial hemorrhage with catheter placement, platelet count ≥ 125,000/µl is required for the patient to undergo biopsy and catheter insertion, which can be attained with the help of platelet transfusion; * Hemoglobin ≥ 9 gm/dL prior to biopsy; * Absolute neutrophil count (ANC) ≥ 1000 cells/mm3 prior to biopsy; * Serum creatinine ≤ 1.5 x the upper limit of normal (ULN) prior to biopsy; * Liver Function: Total bilirubin ≤ 1.5 x ULN prior to biopsy (Exception: Patient has known Gilbert's Syndrome or patient has suspected Gilbert's Syndrome, for which additional lab testing of direct and/or indirect bilirubin supports this diagnosis. In these instances, a total bilirubin of ≤ 3.0 x ULN is acceptable.); AST (aspartate aminotransferase)/ALT (alanine aminotransferase) ≤ 2.5 x the ULN prior to biopsy; * Prothrombin (PT) and activated Partial Thromboplastin Time (aPTT) ≤ 1.2 x upper limit of normal (ULN) prior t…